Is NCNA or NERV more undervalued in 2026?

CirclFi compares NuCana plc (NCNA) and Minerva Neurosciences, Inc (NERV) using 13 institutional-grade valuation models. NCNA has a Quality of Company score of 1.7/10 while NERV scores 3.4/10.

Which is a better buy — NCNA or NERV?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NCNA and NERV valuations compare?

NCNA at $2.33 and NERV at $4.91 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NCNA vs NERV Valuation Comparison 2026 — Intrinsic Value Analysis

NCNA

Pharmaceutical Preparations

NuCana plc

Quality

1.7

out of 10

Value Trap

—

Price

$2.33

Last close

Models

6/13

Active

NERV

Pharmaceutical Preparations

Minerva Neurosciences, Inc

Quality

3.4

out of 10

Value Trap

SAFE

Price

$4.91

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	NCNA Fair Value	NCNA Upside	NERV Fair Value	NERV Upside
Bayesian DCF	Intrinsic	$0.54	-76.8%	$1.70	-65.3%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.98	+71.0%	—	—
PWERM	Option-Based	—	—	$11.74	+139.1%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NCNA vs NERV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NCNA vs NERV — Which Stock Is More Undervalued?

NERV scores higher with a 3.4/10 quality rating vs NCNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NuCana plc (NCNA) and Minerva Neurosciences, Inc (NERV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NCNA currently trades at $2.33 with a QOC of 1.7/10, while NERV trades at $4.91 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).